- Home
- FLY vs GKOS Comparison
FLY vs GKOS Comparison
Compare FLY & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLY
- GKOS
- Stock Information
- Founded
- FLY 2017
- GKOS 1998
- Country
- FLY United States
- GKOS United States
- Employees
- FLY N/A
- GKOS N/A
- Industry
- FLY Military/Government/Technical
- GKOS Medical/Dental Instruments
- Sector
- FLY Industrials
- GKOS Health Care
- Exchange
- FLY Nasdaq
- GKOS Nasdaq
- Market Cap
- FLY 7.1B
- GKOS 5.8B
- IPO Year
- FLY 2025
- GKOS 2015
- Fundamental
- Price
- FLY $53.62
- GKOS $86.99
- Analyst Decision
- FLY
- GKOS Strong Buy
- Analyst Count
- FLY 0
- GKOS 12
- Target Price
- FLY N/A
- GKOS $131.17
- AVG Volume (30 Days)
- FLY 14.2M
- GKOS 1.3M
- Earning Date
- FLY 01-01-0001
- GKOS 07-30-2025
- Dividend Yield
- FLY N/A
- GKOS N/A
- EPS Growth
- FLY N/A
- GKOS N/A
- EPS
- FLY N/A
- GKOS N/A
- Revenue
- FLY $108,330,000.00
- GKOS $432,953,000.00
- Revenue This Year
- FLY N/A
- GKOS $27.88
- Revenue Next Year
- FLY N/A
- GKOS $27.76
- P/E Ratio
- FLY N/A
- GKOS N/A
- Revenue Growth
- FLY 10.06
- GKOS 26.70
- 52 Week Low
- FLY $49.11
- GKOS $77.10
- 52 Week High
- FLY $73.80
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- FLY N/A
- GKOS 35.25
- Support Level
- FLY N/A
- GKOS $84.58
- Resistance Level
- FLY N/A
- GKOS $90.30
- Average True Range (ATR)
- FLY 0.00
- GKOS 3.63
- MACD
- FLY 0.00
- GKOS -0.66
- Stochastic Oscillator
- FLY 0.00
- GKOS 26.81
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.